O-RAN-ALLIANCE
The O-RAN ALLIANCE successfully conducted its second worldwide plugfest and proof of concept to demonstrate the functionality as well as the multi-vendor interoperability of O-RAN based network equipment. At four venues across the globe, in total 55 companies came together to deal with the functional, interoperability and performance challenges of the O-RAN ecosystem. Test scenarios have successfully passed, proving the readiness of O-RAN implementations for commercial rollout.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015006071/en/
“Testing and integration are crucial for developing a commercially available open RAN ecosystem and that’s why the O-RAN ALLIANCE provides its member companies with an efficient global plugfest framework, which complements the O-RAN specification effort as well as the O-RAN Software Community,” said Andre Fuetsch, Chairman of the O-RAN ALLIANCE and Chief Technology Officer of AT&T. “The joint, open, and coordinated effort greatly accelerates the technical evaluation of O-RAN solutions and effectively avoids duplication of efforts for all involved parties whether network operators or solution providers.”
Asia
The O-RAN plugfest/PoC in East Asia was conducted in various operator and vendor labs in Japan and China. Activities in Japan were hosted by NTT DOCOMO, KDDI and SoftBank Corp., and activities in China were hosted in China OTIC labs. One set of scenarios focused on multi-vendor interoperability using O-RAN’s open interfaces: Open Fronthaul (OFH), Fronthaul Multiplexer (FHM), X2, A1, E2, F1 and E1. Other set of scenarios also involved RAN virtualization and RAN Intelligent Controllers (RIC). The East Asian plugfest was supported by 16 companies. Apart from the hosts there were: Altran, Astri, CIG, Fujitsu, JMA Wireless, Keysight Technologies, Kyocera, Mavenir, NEC, NXP, Radisys, Samsung and Toshiba.
Naoki Tani, Executive Vice President and Chief Technology Officer of NTT DOCOMO, commented: "We believe widespread availability of O-RAN compliant solutions will enable building highly flexible 5G networks, and are pleased with the expansion and enhancement of multi-vendor RAN activities observed in this 2nd O-RAN plugfest. The Japan venue, co-hosted with KDDI and SoftBank Corp., also saw growing participation and demonstration of new capabilities. We will strengthen such joint activities, including to set up Open Test and Integration Centre in Japan and to coordinate with other regions across the globe, to further accelerate the development of O-RAN multi-vendor ecosystem."
Hosted by Bharti Airtel, the India plugfest was held at Gurgaon and Bengaluru locations. Demonstrations showcased OFH multi-vendor interworking, O-DU system validation, X2 interface and RIC use cases compliant with O1 and E2 interfaces for network performance optimization. 10 companies performed the scenarios, including: Altiostar, Altran, ASOCS, Mavenir, NEC, STL, VIAVI Solutions, VVDN and Xilinx.
“It is heartening to note that the O-RAN ALLIANCE continues to build the momentum towards open RAN. The successful plugfest this year is a testimony of a maturing ecosystem. Airtel remains committed to build community of open RAN partners in India, to scale our 4G network initiatives based on O-RAN and getting ready for deployment of 5G networks,” said Randeep Sekhon, CTO, Bharti Airtel. “I would like to compliment O-RAN ALLIANCE, its Test and Integration Focus Group, all hosts and participating companies for putting up excellent demonstrations despite challenges of a global Covid-19 pandemic.”
Europe
Deutsche Telekom, TIM, Telefónica, Orange, and BT have teamed up together with the Telecom Infra Project (TIP) to host the first Joint O-RAN & TIP plugfest at the OTIC and TIP community labs in Berlin, Madrid and Torino. The plugfest focused primarily on Open Fronthaul, associated transport options, and multi-vendor interoperability.
In total 34 companies took part at the European branch of the plugfest. With EANTC as the system integrator, supported by engineers from highstreet technologies and the hosting operators, there were: Altran, Astri, Baicells, Benetel, Calnex, Ciena, Cisco, CommScope, Delta, EXFO, Foxconn, Fujitsu, JMA Wireless, Juniper Networks, Keysight Technologies, Mavenir, MTI mobile, ng4T, QCT, Radisys, Rohde&Schwarz, VIAVI Solutions, Wind River, Wiwynn, WNC and Xilinx.
“The joint O-RAN and TIP Plugfest demonstrates the power of community to accelerate the readiness of multi-vendor O-RAN compliant network infrastructure. It was the first time that operators across Europe joined forces to welcome ecosystem partners and facilitate the verification, integration and testing of their disaggregated RAN components,” said Alex Choi, COO of the O-RAN ALLIANCE and SVP Technology Strategy & Technology Innovation, Deutsche Telekom. “This coordinated European community effort represents another step towards the realization of a robust ecosystem of multi-vendor O-RAN compliant products.”
North America
The joint O-RAN & O-RAN Software Community (OSC) Plugfest/PoC hosted by AT&T and Verizon took place at the Platforms for Advanced Wireless Research in New York City and in Salt Lake City. The primary focus was to demonstrate the evolution of key O-RAN specifications in conjunction with the enhancements and new capabilities being delivered by the O-RAN Software Community “Bronze” release . 10 companies joined forces at the North American plugfest, including Accelleran, Cisco, Ericsson, highstreet technologies, Kumu Networks, Mavenir, Nokia and VMware.
O-RAN Plugfest Virtual Showcase
To provide a more detailed and interactive view on the plugfest, O-RAN ALLIANCE is preparing its Plugfest Virtual Showcase. Open to the general public, the visitors will have a chance to see the O-RAN plugfest environment, the test scenarios as well as the components that were tested. The O-RAN Plugfest Virtual Showcase will soon become part of the www.o-ran.org website.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 230 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN-compliant mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations. For more information please visit www.o-ran.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015006071/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
